Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment
Recent Articles
Ruxolitinib Approved for Chronic Graft-Versus-Host Disease
The FDA has approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years and older whose disease...
Crizanlizumab Approved for Sickle Cell Disease in the U.K.
Crizanlizumab will become the first new therapy in 20 years to be made available through the U.K.’s National Health Service (NHS) for the treatment...
FDA Halts Allogene Cell Therapy Trials
The U.S. Food and Drug Administration (FDA) has placed a hold on Allogene Therapeutics’ cell therapy clinical trials following a report of a chromosomal...
Pilot Study Finds Remote Monitoring of Patients Undergoing Chemotherapy Feasible
Using technology to monitor outpatients undergoing cancer treatments at home was feasible and led to improvements in care, according to results of a pilot...
Could AP-Led Quality and Safety Grand Rounds Improve Patient Outcomes?
Grand rounds provide an opportunity for oncology advanced practitioners (APs) to discuss quality and safety across disciplines and may have positive effects on patient...
Current Issue
October 2021, Volume 7, Issue 12
This issue tells the long story of drug shortages, demystifies transfusion services, and more.